Bioaffinity Technologies, Inc. (BIAF) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Bioaffinity Technologies, Inc. (BIAF) stock forecast summary
Our AI ranks Bioaffinity Technologies, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for BIAF is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BIAF included.
Follow BIAF freeBIAF price chart and AI forecast
How BIAF ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Bioaffinity Technologies, Inc. (BIAF) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | BIAF | Rank |
|---|---|---|
| EPS | $-9.13 | – |
Profitability & Margins
| Metric | BIAF | Rank |
|---|---|---|
| ROE | -402.9% | 9/10 |
| ROA | -199.3% | 11/13 |
| Operating Margin | -209.8% | 9/13 |
| Net Margin | -257.3% | 8/11 |
| EBT Margin | -257.2% | 9/13 |
| Tax Rate | -0.3% | – |
Financial Health
| Metric | BIAF | Rank |
|---|---|---|
| Current Ratio | 1.44x | 5/16 |
| Quick Ratio | 1.41x | 4/6 |
| D/E Ratio | 1.02x | 6/11 |
| Financial Leverage | 2.02x | 6/11 |
| Interest Coverage | -249.2x | 9/13 |
| Working Capital | $1M | 6/15 |
Cash Flow
| Metric | BIAF | Rank |
|---|---|---|
| Operating Cash Flow | -$11M | 12/15 |
| Free Cash Flow | -$12M | 4/7 |
| Capital Spending | -$90K | 1/7 |
| FCF/Sales | -195.9% | 7/8 |
| CapEx/Sales | 1.6% | 7/8 |
Operational Efficiency
| Metric | BIAF | Rank |
|---|---|---|
| Asset Turnover | 0.77x | 3/9 |
| Fixed Assets Turnover | 18.8x | 2/9 |
Income Statement
| Metric | BIAF | Rank |
|---|---|---|
| Total Revenue | $5M | 7/8 |
| Operating Income | -$12M | 11/15 |
| Net Income | -$15M | 9/13 |
| R&D Expense | $1M | 6/7 |
| SG&A Expense | $11M | 9/12 |
Dividend & Shareholder Information
| Metric | BIAF | Rank |
|---|---|---|
| EPS Growth | -251.9% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4M | 50.8% of assets |
| Cash & Short-term Investments | $2M | 31.9% of assets |
| Inventory | $80K | 1.0% of assets |
| Total Liabilities | $4M | 50.5% of assets |
| Short-term Debt | $2M | 22.4% of assets |
BIAF quarterly financials and insider trading
Bioaffinity Technologies, Inc. (BIAF) industry peers
Companies classified under the same SEC industry code as Bioaffinity Technologies, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| INCY Incyte Corp | ▼ | $21.70B |
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| OABI Omniab, Inc. | ▲ | $683M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $24M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▲ | $3M |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
Where BIAF sits on the market map
Bioaffinity Technologies, Inc. (BIAF) stock news
Loading...
Bioaffinity Technologies, Inc. (BIAF) stock forecast FAQ
What is the Bioaffinity Technologies, Inc. (BIAF) stock forecast?
Our AI ranks Bioaffinity Technologies, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Bioaffinity Technologies, Inc. stock predictions?
A per-ticker accuracy statistic for BIAF is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bioaffinity Technologies, Inc. forecasts updated?
Bioaffinity Technologies, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Bioaffinity Technologies, Inc.'s industry peers?
16 issuers in our coverage, BIAF included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.